Sanofi Looks To Build On Dupixent Dominance With OX40L Drug
Amlitelimab Could Be Dosed Less Frequently
Sanofi is looking to build its position in immunology, with a new anti-inflammatory candidate, amlitelimab, which could potentially help patients who do not respond to its blockbuster Dupixent.
